JPWO2024262491A1 - - Google Patents

Info

Publication number
JPWO2024262491A1
JPWO2024262491A1 JP2025528066A JP2025528066A JPWO2024262491A1 JP WO2024262491 A1 JPWO2024262491 A1 JP WO2024262491A1 JP 2025528066 A JP2025528066 A JP 2025528066A JP 2025528066 A JP2025528066 A JP 2025528066A JP WO2024262491 A1 JPWO2024262491 A1 JP WO2024262491A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025528066A
Other languages
Japanese (ja)
Other versions
JPWO2024262491A5 (cg-RX-API-DMAC7.html
JP7904995B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2024262491A1 publication Critical patent/JPWO2024262491A1/ja
Publication of JPWO2024262491A5 publication Critical patent/JPWO2024262491A5/ja
Application granted granted Critical
Publication of JP7904995B2 publication Critical patent/JP7904995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2025528066A 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶 Active JP7904995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (3)

Publication Number Publication Date
JPWO2024262491A1 true JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
JPWO2024262491A5 JPWO2024262491A5 (cg-RX-API-DMAC7.html) 2026-06-11
JP7904995B2 JP7904995B2 (ja) 2026-08-13

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025528066A Active JP7904995B2 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
WO2020241853A1 (ja) * 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
JP2022520442A (ja) * 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
CN114507181A (zh) * 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
JP2023038270A (ja) * 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP2023524207A (ja) * 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
WO2023132369A1 (ja) * 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
JP2023038270A (ja) * 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP2022520442A (ja) * 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
WO2020241853A1 (ja) * 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
JP2023524207A (ja) * 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
CN114507181A (zh) * 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
WO2023132369A1 (ja) * 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NARAYANAN, DILIP ET AL.: "Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery", J. MED. CHEM., vol. 65, JPN6024028439, 2022, pages 14481 - 14526, ISSN: 0005886911 *

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
BR102023005164A2 (cg-RX-API-DMAC7.html)
BR102022025291A2 (cg-RX-API-DMAC7.html)
BR112025020304B1 (pt) Liga de solda, esfera de solda, pré-forma de solda, junta de solda e circuito
BR112025008516B1 (pt) Método tudo em um de recuperação de níquel para recuperar níquel a partir de matérias-primas contendo níquel
BR112025016688B1 (pt) Compostos e composições farmacêuticas
BR112025011041B1 (pt) Dispositivo para inspeção de um elemento roscado e método de inspeção correspondente
BR112024022558B1 (pt) Polipeptídeo, polinucleotídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, e, método in vitro para aumentar adesão celular
BR112025005915B1 (pt) Gerador, dispositivo e método de ablação de campo pulsado
BR102023016405B1 (pt) Estrutura de viga de pá, pá de energia eólica e equipamento de energia eólica
BR112024026850B1 (pt) Triturador de mandíbula e método de serviço ou de manutenção de um triturador de mandíbula
BR112024025233B1 (pt) Método para alterar o estado de elevação vertical para um veículo transportador, controle e veículo
BR102023009702B1 (pt) Dispositivo para alisamento e aplicação de substância de tratamento
BR112024027500B1 (pt) Polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, uso do polipeptídeo, e, método para promover a proliferação de uma célula in vitro
BR102023002997B1 (pt) Um aparelho para detecção de vazamento de um gás e um método e um sistema do mesmo
BR112024018530B1 (pt) Método para determinar nível de escória do alto-forno, método para operar alto-forno e unidade de controle
BR112024027130B1 (pt) Sistema e método para um conjunto de cuff (balão) de tubo endotraqueal
BR102022026432B1 (pt) Dispositivo de transferência de esforços transversais em juntas de dilatação
BR102022023712B1 (pt) Sistema de montagem de estrutura flexível para estufas agrícolas, com sistema molejante de movimentação em relação à ação dos ventos
BR122025008972A2 (pt) Sistema, método para decodificar um vídeo e mídia legível por computador
BR122025008973A2 (pt) Sistema, método para decodificar um vídeo e mídia legível por computador
BR122025008970A2 (pt) Método para decodificar um vídeo, sistema e mídia legível por computador
BR102022012728B1 (pt) Unidade para visualização do reinício de escoamento de fluidos dependentes do tempo
BR102022009310B1 (pt) Sistema de montagem para as linhas de adubo de implementos agrícolas
BR102022009015B1 (pt) Válvula anti-congelamento para drenagem em circuitos hidráulicos de aquecedores solares, com sistema termomecânico de expansão e contração
BR112023000644B1 (pt) Dispositivos vestíveis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260602

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260602

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260731